Astellas Pharma announced on August 17 that it has entered into a memorandum of understandings (MOU) with UMN Pharma Inc. for the cell culture-based influenza vaccines developed by UMN Pharma UMN-0501 and UMN-0502. A definitive agreement is planned to be…
To read the full story
Related Article
- UMN, Astellas Agree on Termination of Joint Flu Vaccine Programs
March 13, 2017
- Astellas Bows Out from Flu Vaccine Development Pact with UMN
January 11, 2017
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





